Clene Inc. (CLNN): R&D Expense
$14.01M
Year ended 2025-12-31
$12.82M
Trailing 12 months to 2026-06-30
-24.0%
3-year compound annual growth
-1.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.01M | -30.1% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $20.06M | -24.7% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $26.66M | -16.5% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $31.92M | +12.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $28.42M | +86.9% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $15.20M | +59.0% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $9.56M | n/a | 2021-03-29, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Clene Inc. (CLNN) | 2025-12-31 | $14.01M | -30.1% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $7.95M | -29.9% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
Compare CLNN, LSTA, RGBP, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗